OBJECTIVES: Pulmonary sarcomatoid carcinoma (PSC) is a rare histological subtype of non-small cell lung cancer and comprises a diagnostically and therapeutically challenging group of tumours. We explored the clinicopathological features and prognostic factors of this tumour.
INTRODUCTION
Most clinical trials on lung cancer are focused on adenocarcinoma or squamous cell carcinoma (SCC) but pathological subclassifications are becoming increasingly important for treatment decisions and thus even the less common tumours need to be investigated in such studies.
Primary sarcomatoid carcinoma (PSC) of the lung is a rare subtype of non-small cell lung cancer (NSCLC), accounting for 0.1-0.4% of all lung malignancies [1] . There are only a few publications on this tumour entity [2] . PSC is defined as poorly differentiated non-small cell carcinoma (in particular, SCC, adenocarcinoma or undifferentiated non-small cell carcinoma) that contains a component of sarcoma or sarcoma-like elements (at least 10% spindle and/or giant cells) or a carcinoma consisting only of spindle and giant cells [1, 3] . Since 2004, PSC has been classified according to the World Health Organization grading system as pleomorphic carcinoma, spindle cell carcinoma, giant cell carcinoma, carcinosarcoma or pulmonary blastoma [1] . Based on the clinical presentation and imaging, several differential diagnoses must be considered, including subtypes of sarcomatoid carcinomas as well as primary or secondary metastatic sarcoma, malignant melanoma and pleural mesothelioma [1] . A preoperative diagnosis is often difficult due to the heterogeneity of these tumours [4] . Considering this remarkable morphological diversity as well as the possible differential diagnoses, histopathological diagnostics may be very challenging. This is compounded by the fact that in small biopsies some tumour components (e.g. adenocarcinoma, SCC, large cell carcinoma, etc.) may be under-/overrepresented or totally missing, which may be misleading and hinder the definitive diagnosis from these small samples [4] . For the reasons mentioned above extensive tumour sampling is recommended from the pathologist [1, 4] . In indistinct cases, additive immunohistochemical staining (e.g. cytokeratin and differentiationassociated markers such as TTF-1, Napsin A, P40, Vimentin, Desmin, Myogenin, epithelial membrane antigen, carcinoembryonic antigen, CD31, CD34, Melan A, S100, Ber-Ep4, WT1 and D2-40) has been found to be helpful in highlighting the diverse cell types and indicating potential differential diagnoses [1, 4] . It should be noted that cytokeratins are not required if nonpleomorphic carcinoma components are clearly present [1, 4] . PSC often affects older adults with a mean age of 60-70 years, mainly males and smokers. The reported prognosis is poor, with a mean survival of 9-12 months in patients with complete tumour resection and a 5-year survival of approximately 20% [5] [6] [7] [8] [9] [10] .
At presentation, tumours are often large and either centrally invading the proximal airways and vessels or peripherally invading the chest wall [7, 11] .
In completely resected stage IIa-IIIa NSCLC, adjuvant cisplatinbased chemotherapy has been shown to improve overall survival in several large, randomized clinical trials [12, 13] . Neoadjuvant chemo-or radiochemotherapy approaches in patients with N2 diseases or T4 tumours are also established and show a survival benefit [14] . Existing data about the effect of chemotherapy on PSC is controversial. Vieira et al. [15] and Yendamuri et al. [16] found that PSC were associated with resistance to conventional chemotherapy. In advanced disease others have described nonrespondence to palliative chemotherapy [17] . A positive effect on PSC with postoperative chemotherapy was shown by Huang et al. [18] . Due to the rarity of presentation the prognosis and best treatment for this group of malignancies remains uncertain.
Our study was conducted to evaluate patient characteristics, pathological results, survival and prognostic factors of this rare disease in our hospital and compare them with other series.
MATERIALS AND METHODS

Study design
Our study protocol was approved by the ethics committee of the Medical Faculty of the University of Duisburg-Essen (13-5363-BO) and informed consent was obtained from all patients who were alive. All patients were identified from a prospective clinical database and from the pathology database. All were treated for PSC at the Department of Thoracic Surgery, Ruhrlandklinik Essen (Germany), from May 2005 to December 2014, and were retrospectively analysed. Data were obtained from the medical records, pathology reports and the cancer centre database. Referring specialists were asked for missing values and in some cases patients or their relatives were contacted for further information. Standard oncological staging included computed tomography (CT) of the chest and abdomen, magnetic resonance imaging of the head, and bone scintigraphy. In the last 4 years of the study period, positron emission tomography (PET) was integrated into the standardized staging procedure when appropriate. Suspicious mediastinal nodes were further investigated with endobronchial ultrasound (EBUS) and transbronchial needle aspiration (TBNA) or mediastinoscopy, as appropriate. The clinical stage was determined for each patient by incorporating all preoperative staging procedures, according to the current European Society for Medical Oncology (ESMO) staging guideline.
Patients were surgically treated with the goal of complete resection. Frozen section analysis was used to confirm free margins when necessary. Anatomical resection was combined with systematic lymph node sampling or systematic dissection at the discretion of the surgeon. Patients with N3 disease or distant metastases were precluded from curative surgery. When mediastinal N2 disease was confirmed preoperatively by mediastinoscopy or EBUS-TBNA, neoadjuvant chemo-or chemoradiotherapy was prescribed and surgery performed in resectable cases without disease progression. Adjuvant chemotherapy was applied in cases with stage II (diameter >4 cm) or stage III disease and adjuvant radiotherapy in cases with confirmed N2 disease.
Statistical analysis
Overall survival was defined as the time interval between the date of operation and the date of death or the last follow-up visit. All patients alive at the latest follow-up were censored. KaplanMeier analysis was used to compute univariate comparisons between different subsets, including overall survival, T status, N status and local lymphatic spread. To compare the survival distributions of 2 samples, we applied the log-rank test. Differences with P < 0.05 were considered statistically significant. Statistical analysis was performed with SPSS 22.0 (SPSS Inc., Chicago, USA).
RESULTS
Patient characteristics and treatment
In weight loss of more than 10% of their body weight within the last 3 months. PET-CT scan was performed in 25 operated patients with an average maximum standardized uptake value (SUV max ) of 14.3 ± 3.1 in the primary tumour.
Among the 58 patients, 12 presented with a diffuse metastasized disease and were treated with palliative chemotherapy. In 3 cases palliative radiotherapy was added. A total of 5 patients had pleural dissemination and diffuse pulmonary metastases, 5 had diffuse hepatic metastases and 2 patients had multiple bone metastases. The histopathological diagnosis in these palliative patients was obtained by bronchoscopy in 7 and pleural biopsies via thoracoscopy in 5 patients. The median survival of these 12 palliative patients was 4.5 months. Only 1 of these patients received carboplatin-based chemotherapy first line and a tyrosine kinase inhibitor within a Phase II study protocol. He survived 2 years.
Operative results
Primary resection was performed in 38 (82.6%) potentially resectable patients, and neoadjuvant chemoradiotherapy (total dose of 45 Gy) followed by complete resection was applied to 3 patients due to preoperative N2 involvement. One patient received only induction chemotherapy (4 cycles cisplatin/paclitaxel) (Figure 1) . A clinical or radiological partial response to induction chemoradiotherapy or only chemotherapy was observed in all patients (100%). Four patients had oligometastatic stage IV disease, including a single skin metastasis of the chest wall in 1 patient, which was simultaneously resected during thoracotomy, a single brain metastasis in 2 patients and a single adrenal gland metastasis. All of them were completely resected before lung resection. The 3 patients with the brain and adrenal metastases received 2-4 cycles of neoadjuvant platin-based chemotherapy.
The mean age at surgical intervention was 67 (35-80) years. The correct histological diagnosis of PSC was established preoperatively in only 6 cases, 3 of them through resection of the single metastasis. Eight cases were diagnosed as NSCLC not otherwise specified via bronchoscopy. In all other cases the correct histological diagnosis was first established from the resected primary ( Figure 2) .
The main surgical procedure was lobectomy in 34 (73.9%), sleeve lobectomy in 3 (6.5%), bilobectomy in 2 (4.4%) and pneumonectomy in 4 (8.7%) cases (Table 1) . Furthermore anatomical segmentectomy was performed in 3 (6.5%) cases due to an impaired pulmonary function. In 11 cases, an extended lobectomy with chest wall resection was necessary. The 30-day postoperative mortality was 2.2%, including 1 patient with pneumonia and respiratory failure after extended chest wall resection. Complete resection (R0) was achieved in 97.9% and R1 in 1 patient with chest wall involvement. Systematic lymphadenectomy was performed in 44 (95.7%) cases and lymph node sampling in 2 (4.3%) cases. The mean number of lymph nodes removed was 11.4 ± 5.4 (range 2-24).
Pathological findings
The postoperative pathological examination revealed a mean tumour size of 5.4 cm (range 1.6-11.0 cm). There were 25 (54.4%) carcinosarcomas, 10 (21.7%) pleomorphic carcinomas, 7 (15.7%) spindle cell carcinomas, 3 (6.5%) giant cell carcinomas and 1 (2.2%) pulmonary blastoma. The postoperative tumour stages were IA in 4 (8.7%), IB in 7 (15.2%), IIA in 9 (19.6%), IIB in 15 (32.6%), III in 7 (15.2%) and IV in 4 patients (8.7%) according to the seventh edition of the American Joint Committee on Cancer (AJCC) staging system. Mismatches and underestimation (cN < pN) in clinical and pathological nodal staging were found in 1 patient (cN1 ! pN2). The pathological nodal stage was pN0 in 20 (43.5%) patients, pN1 in 18 patients (39.1%), pN2 in 1 (2.2%) patient, ypN0 in 5 (10.9%) patients and ypN1 in 2 (4.3%) patients. Although we tested several immunohistochemical markers, no prognostic marker could be identified.
Adjuvant treatment
Among the surgically resected patients, 18 received 4 complete cycles of adjuvant platin-based chemotherapy (cisplatin/paclitaxel or cisplatin/vinorelbine). The 1 incidental pN2-positive patient also received mediastinal irradiation. The patient with R1-resection of the chest wall received local adjuvant radiation therapy.
Survival analysis
None of the operated patients was lost to follow-up. The median follow-up was 30 months (range 3-113 months). Of the 46 patients with resected PSC, 28 (60.9%) died in this period. All patients died from recurrent cancer. Recurrence was distant disease in 12, local recurrence in 8 and combined distant and local recurrence in 8 patients. Six (21.4%) patients with recurrence were rebiopsied and all of them showed recurrent PSC. The mean interval between surgery and detection of recurrence was 6.8 months.
The overall 1-, 3-and 5-year survival rates were 57.7, 35.8 and 28.7% of all operated cases (Figure 3) , respectively. The median survival in stages I, II, III and IV was 44.9, 14.9, 10.2 and 5.6 months, respectively. Survival was not significantly associated with sex, histology, vascular (V1) or lymphatic vessel (L1) spread. We saw a trend for younger patients (<65 years) to have better survival than older patients (> _65 years) (P = 0.055) (Figure 4) . There was also a trend to better survival for patients with a T1 or T2 tumour compared to T3 and T4 cases (P =0.051), but this did not reach a statistically significant level ( Figure 5 ).
DISCUSSION
PSC is very uncommon and represents <1% of all NSCLCs. Compared with other histological subtypes, PSC behaves in an aggressive way [18] , growing rapidly and frequently involving the adjacent lung, chest wall, diaphragm, pericardium and other tissues at the time of diagnosis [2] . In our series 20.8% of the patients that presented with a sarcomatoid carcinoma had distant disease and were treated in a palliative context. Beside the locally aggressive character, no specific signs or symptoms have been found for PSC when compared with other typical NSCLCs [19, 20] . As reported in other series, there was no evidence of any difference from other NSCLCs in the initial symptoms of our treated patients. PSC appears mostly in men and in patients >60 years, except for the pulmonary blastoma subtype, which occurs in younger patients [9, 10] .
In this series, the male to female ratio was 1.5:1 and 96.6% of the patients had a history of smoking or were still smoking, which is consistent with the characteristics of other published series [20] .
Preoperative pathological diagnosis failed to identify this tumour type in most cases, mainly due to the excessive cellular heterogeneity. In this series, preoperative pathological diagnosis was attempted in 30 patients who were destined for surgical resection. Fourteen were diagnosed with malignancy, but only 6 patients had a preoperatively confirmed PSC. Cases with tumour recurrence or advanced inoperable stages could all be confirmed as PSC by bronchoscopy or CT-guided fine-needle biopsy.
Some reports show that positron emission tomography uptake is much higher in sarcomatoid carcinomas than other NSCLCs [21] . In our study we also found a high standardized FDG uptake (SUV) of 14.3 ± 3.1 and therefore primary tumours with a high SUV might be indicative of sarcomatoid carcinoma. This should be verified by further studies with more patients and subdifferentiation of the NSCLC types.
In the absence of other data the treatment approach for PSC is similar to that for other NSCLCs. Therefore, induction chemo-or chemoradiotherapy or adjuvant chemotherapy is indicated in stages IB-IIIA. If possible a surgical resection should be performed. Out of 58 patients with a sarcomatoid carcinoma, 46 were operated either with or without perioperative chemotherapy. As other authors have mentioned previously, this tumour entity tends to grow in a peripheral location and often invades the chest wall, so chest wall reconstruction is frequently needed. In the current series, 11 of 46 patients (23.9%) had chest wall invasion and resection in combination with a lobectomy. Other extended resections such as bilobectomy, pneumonectomy or sleeve resection were necessary in 9 cases (18.7%). This is consistent with reports that extended resections, such as chest wall resection, bilobectomy or pneumonectomy are more frequently performed in PSC than in other NSCLCs [22] .
The overall 1-, 3-and 5-year survival probabilities of all operated cases in our series were 57.7, 35.8 and 28.7%, respectively. This is clearly inferior to the survival of other NSCLC patients with an overall survival in stage IA of 75-80% and 55-60% in stage IB [23, 24] . The postoperative overall survival for patients with NSCLC in stage IIA and IIB are still 45-55 and 35-45% [25] .
But it must be remembered that the proportion of sarcomatoid elements usually correlates with tumour size, and it is therefore possible that smaller, earlier-stage tumours may not contain sufficient sarcomatous elements to negatively impact survival compared with typical NSCLC [26] .
Within a similar study Huang et al. [18] presented comparable results with 1-, 3-and 5-year overall survival rates of 45.5, 28.2 and 20.1%. They also found that tumour size is an independent prognostic factor. This could not be affirmed in our study. Our analysis revealed a trend that age >65 was associated with worse overall survival. (Table 2) Martin et al. also showed 3-and 5-year survival rates of 34.9 and 24.5%, which are similar to our results [27] . The impressive 5-year survival rate of 54.3%, reported by Park et al. [2] , might be explained by the predominance of pleomorphic sarcoma (90.9%) (including only 1% carcinosarcoma) and thus the rather homogeneous collective of patients. Some authors have reported resistance to conventional chemotherapy whereas other authors have demonstrated that perioperative chemotherapy is associated with increased overall survival [18] . In our study all patients that received preoperative chemotherapy or radiochemotherapy showed a radiological response in the form of tumour regression, and thus we cannot support the statement that sarcomatoid carcinomas are resistant to chemotherapy. In some selected cases induction chemotherapy might be reasonable in locally advanced disease. Nevertheless, there was no apparent benefit for patients with perioperative chemotherapy according to overall survival.
The question must nevertheless be asked whether surgery alone is enough for local tumour control, taking into account the high rate of local recurrence after R0 resection. Furthermore the low survival rates even in early stages rise the question if multimodality treatment may be necessary in all stages.
Limitations
This study suffers from the inherent treatment selection bias associated with any retrospective analysis and the small number of cases, which is due to the rarity of PSC. Future studies with larger patient populations must re-evaluate the influence of histological subtypes and other prognostic factors so that we can obtain statistical power.
CONCLUSIONS
Primary sarcomatoid carcinomas represent a small group of NSCLCs that are often diagnosed in a locally advanced stage and therefore extended surgical resections are needed more often compared with other NSCLCs. The overall survival after surgical therapy is lower than in other NSCLCs even in stage I or II, so extensive surgery must be carefully planned, balancing benefits and losses. There is no clear evidence that chemotherapy prolongs survival.
